



## ***BELEAVE STRENGTHENS ADVISORY BOARD WITH ADDITION OF PAUL EVANOV***

**Toronto, ON – January 5, 2016 - Beleave Inc.** (CSE: BE) (“Beleave” or the “Company”) is pleased to announce that Paul Evanov has been added to the company’s Advisory Board.

Paul Evanov is a seasoned broadcasting executive with over 20 years experience in the radio and broadcasting industry. Mr. Evanov currently holds the title of Executive Vice President and Program Director at Evanov Radio Group, a company he was instrumental in building to Canada’s largest independent radio broadcaster. Mr. Evanov is currently responsible for the day-to-day operation of 18 radio stations across Canada with approximately 2.7 million weekly listeners.

*“I am extremely excited to be a part of such a significant time in healthcare,” said Paul Evanov. “I look forward to helping the Beleave team gain a competitive advantage in marketing and advertising, as well as increase their exposure by expanding the company’s network through the use of my own.”*

Mr. Evanov was inducted to the Humber College Radio Hall of Fame in 2014 just two years after his father was inducted into the Canadian Music and Broadcast Hall of Fame.

*“On behalf of the Beleave team, we would like to welcome Paul to the Advisory Board,” said Beleave CEO Roger Ferriera, “With Paul as an advisor we will look for guidance in improving our current marketing efforts beyond his radio platforms, where we currently run campaigns. The current composition of the Beleave team provides the company with a broad range of corporate expertise in research, banking, retail, and now marketing.”*

### **Mr. Evanov joins members already on the Beleave Advisory Board including:**

Peter S. Pennefather, Ph.D., is an academic director of the University of Toronto Laboratory for Collaborative Diagnostics and a member of the University of Toronto Centre for the Study of Pain advisory board who is actively involved in various research and education initiatives that promote better awareness of health care imperatives through inter-professional collaboration and public outreach.

David Naranjit, Ph.D., a faculty member in Ryerson University’s Department of Chemistry and Biology since 1985, known for his work in the field of analytical chemistry, particularly in atomic spectroscopy and chromatography.



Justin Kosalka, M.Sc., is trained in materials, synthetic, and analytical chemistry, and has previously worked at the Xerox Research Center of Canada developing novel synthetic and bio-based materials.

**The advisory board with the addition of Mr. Evanov, significantly complements Beleave's Board of Directors, which includes:**

Roger Ferreira, Ph.D., CEO, received his graduate training in the area of neuroimmunology, and has worked as a research scientist at Toronto Western Hospital examining ways to curb brain inflammation that occurs with stroke, traumatic injury, and neurodegenerative disease.

Bojan Krasic, CFO, has 10 years experience as financial services professional. He began his career with Thomas Weisel Partners Canada Inc. and later joined Stifel Nicolaus Canada Inc. Mr. Krasic has experience in finance structuring, providing valuations, fairness opinions, exchange listings and various merger and acquisition transactions.

Andrew Wnek CA, CPA, BCOMM, MBA, a senior financial executive and former Senior Vice President, Finance and Administration at Canadian Tire Corporation who most recently was the National CFO for the Heart and Stroke Foundation.

Bill Panagiotakopolous, COO, has spent 10 years in the real estate development industry as the Owner and CEO Cardinal Group Inc. He has successfully implemented numerous cost-effective bioremediation solutions that convert contaminants into environmentally safe harmless by-products.

For a more in depth look at the Beleave team please visit [www.beleave.com/team](http://www.beleave.com/team)

**About Beleave**

Beleave Inc. (formerly Stream Ventures Inc.) is a biotech company committed to becoming a licensed producer under the *Marihuana for Medical Purposes Regulations* (the "**MMPR**"). Beleave's wholly owned subsidiary First Access Medical Inc. ("**FAM**") has applied for a licence to cultivate and sell medical marihuana pursuant to the MMPR. As of the date hereof, FAM has successfully advanced past the security clearance stage and is currently in the review stage of the licensing process. Beleave's purpose built facility is located near Hamilton, Ontario.

***Forward-Looking Statements***

This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Corporation believes that the expectations and



assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Corporation can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the completion of the MMPR licensing process and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Corporation's disclosure documents, which can be found under the Corporation's profile on [www.sedar.com](http://www.sedar.com).

#### **CONTACT INFORMATION**

Beleave Inc.

[www.beleave.com](http://www.beleave.com)

Sebastian de Kloet

+1-905-979-5173

[Sebastian@beleave.com](mailto:Sebastian@beleave.com)